Review Suggests Skin AEs Rare With PD-1/PD-L1 Inhibitors Review Suggests Skin AEs Rare With PD-1/PD-L1 Inhibitors
Reports of keratoacanthomas and squamous cell carcinomas associated with the use of PD-1/PD-L1 inhibitors appeared to be relatively rare.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 15, 2024 Category: Cancer & Oncology Tags: Dermatology Clinical Summary Source Type: news
Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer
(MedPage Today) -- SAN DIEGO -- Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) who received atezolizumab (Tecentriq) after undergoing multimodal definitive therapy failed to achieve a statistically meaningful... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 10, 2024 Category: Hematology Source Type: news
AACR: Novel Personalized Vaccine Feasible for Head and Neck Cancer
TUESDAY, April 9, 2024 -- The novel viral-based personalized cancer vaccine, TG4050, which encodes up to 30 patient- and tumor-specific sequences is feasible and safe for patients with resected head and neck squamous cell carcinoma, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2024 Category: Pharmaceuticals Source Type: news
Developing and validating a nomogram to predict suicide risk of patients with head and neck squamous cell carcinoma - Deng J, Ai P.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - April 1, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Sarcopenia May Predict FT Placement in Patients With OPSCC Sarcopenia May Predict FT Placement in Patients With OPSCC
Identifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 22, 2024 Category: Pathology Tags: Hematology-Oncology Source Type: news
Sarcopenia Predicts Feeding Tube Placement in OPSCC Patients Sarcopenia Predicts Feeding Tube Placement in OPSCC Patients
Identifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
De-escalating Therapy for Oropharynx Squamous Cell Carcinoma De-escalating Therapy for Oropharynx Squamous Cell Carcinoma
Three new studies exploring treatment de-escalation of HPV-associated oropharynx squamous cell carcinoma added to data showing it ' s possible to reduce toxicity without jeopardizing oncologic outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
New PD-1 Inhibitor Approved for Esophageal Cancer
(MedPage Today) -- The FDA approved tislelizumab (Tevimbra) for advanced/metastatic esophageal squamous cell carcinoma (ESCC) previously treated with chemotherapy, BeiGene announced.
The approval stipulates use of the PD-1 inhibitor in adults... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news
FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FDA Approves Tevimbra (tislelizumab-jsgr) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news
Beta-defensin index: A functional biomarker for oral cancer detection
Cell Reports Mediine AccessPublished:March 04, 2024DOI:https://doi.org/10.1016/j.xcrm.2024.101447SummaryThere is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell-derived anti-microbial peptide, is pro-tumorigenic and overexpressed in early-stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry. The proportion of hBD-3/hBD-2 levels in non-invasivel...
Source: Dental Technology Blog - March 12, 2024 Category: Dentistry Source Type: news
Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news
Ask Dr Rosemary Leonard: Why won't my GP monitor my skin cancer?
A reader wonders if their GP is right not to want to carry out further checks after a raised lump was found to be squamous cell cancer (Source: Daily Express - Health)
Source: Daily Express - Health - March 5, 2024 Category: Consumer Health News Source Type: news
Novel Therapy Promising for Radiation-Induced Oral Mucositis
(MedPage Today) -- The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck who underwent radiation therapy, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news
Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- Gene-guided treatment selection for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) failed to improve disease control versus random treatment selection in a small preliminary clinical trial.
Personalized treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 4, 2024 Category: Hematology Source Type: news
